5-Methyl-4,5,6,7-Tetrahydrothiazolo[5,4-C]Pyridine-2-Carboxylic Acid Hydrochloride

5-Methyl-4,5,6,7-Tetrahydrothiazolo[5,4-C]Pyridine-2-Carboxylic Acid Hydrochloride


    • Product Name 5-Methyl-4,5,6,7-Tetrahydrothiazolo[5,4-C]Pyridine-2-Carboxylic Acid Hydrochloride
    • Alias Relugolix
    • Einecs 681-574-7
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    366828

    Chemical Formula C9H12ClNO2S
    Molecular Weight 233.715 g/mol
    Appearance Solid (usually powder)
    Physical State Solid at room temperature
    Melting Point Data may vary depending on purity
    Solubility Solubility characteristics depend on solvents, may have limited solubility in some organic solvents
    Pka Data may be available from chemical databases for acid dissociation behavior
    Logp Describes lipophilicity, value can be calculated or obtained from databases
    Stability Stability may be affected by temperature, light, and humidity
    Hazard Class Classification may depend on toxicological and safety data, e.g., may be harmful if swallowed, inhaled, etc.

    As an accredited 5-Methyl-4,5,6,7-Tetrahydrothiazolo[5,4-C]Pyridine-2-Carboxylic Acid Hydrochloride factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100g of 5 - Methyl - 4,5,6,7 - Tetrahydrothiazolo[5,4 - C]Pyridine - 2 - Carboxylic Acid Hydrochloride in sealed vial.
    Shipping 5 - Methyl - 4,5,6,7 - Tetrahydrothiazolo[5,4 - c]Pyridine - 2 - Carboxylic Acid Hydrochloride is shipped in sealed, corrosion - resistant containers. Special handling precautions are taken due to its chemical nature, ensuring safe transit.
    Storage Store 5 - Methyl - 4,5,6,7 - Tetrahydrothiazolo[5,4 - c]Pyridine - 2 - Carboxylic Acid Hydrochloride in a cool, dry place. Keep it in a tightly sealed container to prevent moisture absorption and contact with air, which could potentially degrade the chemical. Avoid storing near sources of heat or ignition.
    Application of 5-Methyl-4,5,6,7-Tetrahydrothiazolo[5,4-C]Pyridine-2-Carboxylic Acid Hydrochloride
    Metabolic impurity profiling for the hydrochloride salt begins with forced degradation studies under ICH Q1A(R2) conditions: acid/alkali hydrolysis at 0.1 N HCl/NaOH, oxidative stress with 3% H₂O₂, and thermal challenge at 105°C for 14 days. The product is used as a starting material for synthesizing a ring-opened dimer impurity reference standard required by a generic ANDA filing targeting an oral FXa inhibitor. In this specific downstream application, the hydrochloride salt is spiked into a simulated reaction mixture at 0.15–0.25 wt% relative to the API freebase, mimicking carry-over levels observed during process validation of a telescoped three-step sequence from nitrile hydrolysis to amide coupling. The downstream process involves dissolution in 0.05 M phosphate buffer (pH 6.8), preparative HPLC on a C18 column (250 × 50 mm, 10 µm) with isocratic elution using acetonitrile/water (35:65 v/v, 0.1% TFA), and lyophilization to yield the trifluoroacetate salt as an off-white powder. The terminal deliverable is a sealed ampule containing 25 mg of the impurity standard with a Certificate of Analysis listing purity by HPLC-UV (≥97.0 area%), identity by HRMS, and residual solvents by GC-HS per USP <467>. Compliance reference: 21 CFR 211.84(d)(6) for reserve samples and USP <1225> for validated analytical procedures.

    What Limits Reslurry Purity Upgrade of the Freebase Intermediate Pre-Amide Coupling?

    When the hydrochloride salt is neutralized with 2.0 M NaOH in a Schott Duran glass-lined reactor at 10°C to liberate the freebase, the resulting slurry is filtered and re-slurried in toluene/methylcyclohexane (1:2 v/v) to remove the des-methyl analog and a pink dimeric oxidation byproduct. The molar addition ratio of the neutralizing base is tightly held at 1.02–1.05 equivalents; overshooting beyond 1.08 equivalents induces a pH > 9.8 that deprotonates the thiazole N-H and causes a 12–18% yield loss due to water-solubilization of the anionic species. At 200-L scale, reslurry efficiency sharply depends on jacket temperature ramp: a controlled hold at –5°C for 3 hours with overhead agitation at 120 rpm (retreat-curve impeller) reduces the des-methyl impurity from 0.45 area% to 0.08 area%, whereas a fast ramp to 0°C over 45 minutes leaves the impurity at 0.22 area%, failing the in-process specification of ≤0.10 area% required by the downstream amide coupling segment. The manufacturing process then proceeds with the wet cake being dried in a Büchi spherical dryer at 45°C/10 mbar, yielding the freebase with a water content <0.5% (Karl Fischer) before its use as the nucleophile in an HATU-mediated coupling with a 4-chlorothienylacetic acid derivative. The terminal product is an oral coagulation factor Xa inhibitor compressed into 15 mg and 30 mg film-coated tablets, manufactured under compliance with ICH Q7 Section 8.4 (Recovery of Materials and Solvents) and EU GMP Annex 15.

    FXa Inhibitor Registration Batches — A Three-Stage Chiral Synthesis Review

    Production of the hydrochloride salt with a single enantiomer form (S-configuration at the 5-methyl position) for a direct factor Xa inhibitor requires dynamic diastereomeric crystallization using 0.52 equivalents of L-(-)-dibenzoyl tartaric acid monohydrate in a methanol/water (85:15 v/v) system. The salt addition rate—0.8 g/min per kg of substrate in a 1,000-L glass-lined vessel equipped with a Ekato Paravisc anchor—determines whether the undesired (R)-diastereomer co-crystallizes; a dosing time below 45 minutes causes a local supersaturation spike that embeds 3.8–5.2% of the opposite enantiomer into the crystal lattice, manifested as a 4.6° depression in the final API’s melting point onset by DSC (Mettler Toledo DSC 3+). The downstream production sequence covers: (a) chiral salt resolution, (b) salt-break with aqueous K₂CO₃ to regenerate the S-freebase, (c) carbodiimide-mediated coupling with a pyridine-2-carboximidamide fragment (ratio 1.0:1.2:1.15 = freebase:acid:EDC·HCl) in acetonitrile at 0–5°C, (d) in-line FTIR (ReactIR 15) monitoring the isourea intermediate at 1650 cm⁻¹ until peak area drops below 0.12 AU·min, and (e) acetone/water recrystallization yielding a white needle-like solid. The compliance framework spans FDA 21 CFR 210 and 211, with specific adherence to §211.110 (sampling and testing of in-process materials) and ICH Q6A decision tree #3 for chiral identity testing. The finished dosage form is a 60 mg capsule containing a spray-dried dispersion of the API with HPMCAS-MG to overcome solubility-limited absorption.
    Process StepEquipment ConfigurationCritical Control LimitAcceptance Criterion
    Chiral resolution1,000-L GL reactor, Paravisc anchor, 40 rpmTemperature ramp –5°C/h from 50°C to 10°CS:R enantiomer ratio ≥99.2:0.8
    Freebase liberationHastelloy C22 centrifuge, 0.5 µm PTFE clothpH endpoint 8.3±0.2 at 20°CResidual tartaric acid ≤0.15%
    Amide coupling500-L jacketed vessel, turbine impellerWall ΔT during EDC dosing ≤8°CStep conversion ≥97.5% by HPLC

    When the 5-Methyl Substituent Induces Diastereomeric Salt Resolution Challenges During Optical Purity Upgrade

    Substitution of the routine L-DTTA resolving agent with (S)-(+)-mandelic acid at a 0.48 molar equivalent ratio creates a ternary phase system in toluene/THF (7:3 v/v) where the target diastereomeric salt exhibits a metastable needle habit that undergoes rapid conversion to a platelet polymorph at slurry temperatures above 22°C. The polymorphic shift increases the filtration time across a 0.2 m² Rosenmund filter-dryer from 35 minutes to 2.4 hours, rendering the batch non-viable for the downstream telescoped crystallization that feeds directly into a vial-filling isolator for lyophilized injectable product. In this manufacturing stream, the hydrochloride salt final form is relied upon to generate a parenteral-grade FXa antidote candidate, with the freebase being converted to the chloride salt via HCl gas in isopropanol at –10°C to an endpoint of 0.5 M; the dosing ratio of HCl gas is 1.8–2.0 equivalents relative to the freebase to ensure full protonation of both the piperidine nitrogen and the thiazole nitrogen without excessive acid that decomposes the thiazole ring. Downstream operations include sterile filtration through a 0.22 µm PVDF capsule, hot-air sterilization of vials at 320°C for 6 minutes, and lyophilization with a primary drying shelf temperature of –25°C for 40 hours at 50 Pa. The terminal product is a 15 mL vial containing a sterile, pyrogen-free lyophilized cake equivalent to 100 mg of active moiety, complying with EMA/CHMP/CVMP/QWP/246816/2015 for active substance master file content and USP <1> for injections.How the hydrochloride salt performs as a carboxylate warhead precursor in a KRAS G12C covalent inhibitor conjugate is constrained by the steric demand of the cis-fused tetrahydrothiazolopyridine scaffold. For this program, the salt is first converted to the free carboxylic acid by neutralization with 0.5 N HCl to pH 3.0–3.2, then coupled to a piperazine linker using T3P (propanephosphonic acid anhydride) in DMF at 0.33 M concentration, with the acid:amine:T3P:DIPEA ratio fixed at 1.0:1.05:1.4:2.8. The reactive profile on 50-L scale demands internal temperature control between –3°C and +2°C during T3P addition because the exotherm triggers a retro-Michael elimination of the linker’s acrylamide terminus when the local temperature exceeds +8°C, evidenced by a surge of a UV-active byproduct at RRT 1.57 (HPLC, Waters XBridge C8 column). The coupled intermediate then enters a continuous-flow hydrogenation step using a ThalesNano H-Cube Pro, where the pyridine ring within the fused system is reduced over 10% Pd/C at 50 bar H₂ and 60°C, with a residence time of 3.5 minutes. The terminal product form is an oral solid dosage capsule (20 mg strength) containing the final degrader conjugate co-formulated with Vitamin E TPGS and colloidal SiO₂ to enhance dispersion in fasted-state simulated intestinal fluid. The regulatory submission references ICH M7(R2) for mutagenic impurity control, specifically the purge factor assessment for the thiazole ring-opening impurity at a threshold of toxicological concern of 1.5 µg/day.
    Compliance StandardClause / Test MethodApplication ContextTarget Limit
    ICH Q3C (R8)Class 2 solvent residual limitsDMF, acetonitrile in final APIDMF ≤880 ppm; ACN ≤410 ppm
    FDA 21 CFR 211.67Equipment cleaning and maintenanceDedicated filter-dryer for choreic saltsCross-contamination ≤10 ppm
    EMA/CHMP/ICH/742542/2022In silico prediction of elemental impurity purgePalladium removal post hydrogenationPd ≤ 5 µg/g (oral, permitted daily exposure)
    ICH Q11Starting material justificationDefining the point of GMP introductionHPLC purity of hydrochloride salt ≥99.0 area%

    Molecular Weight Distribution Shift in K₂CO₃-Mediated SNAr Reactions at Multi-Kilo Scale

    When the hydrochloride salt is deployed as a rigid tertiary amine-containing carboxylic acid fragment in an SNAr reaction with 2,4-dichlorothieno[3,2-d]pyrimidine, the heterogeneous base conditions—2.3 equivalents of K₂CO₃ (325 mesh) in DMSO-d6 at 75°C—create a biphasic gel layer if the agitator’s tip speed falls below 1.0 m/s in a 160-L reactor with a single 4-blade pitched-blade turbine. The gel layer traps 14% of the added freebase, lowering the effective molar ratio at the interface to 0.89:1 relative to the electrophile, which sends the reaction into a non-linear kinetic regime where the main product begins to undergo a secondary chloride displacement to form a bis-adduct at 7.3 area% (HPLC retention time 12.8 min versus the desired mono-adduct at 11.2 min). The process remedies the issue by switching to a segmented shaft coaxial mixer (EKATO PARAVISC 2.0) maintaining tip speed at 1.3 m/s and by reverse-addition—metering the electrophile into the freebase suspension over 90 minutes—which restores the mono:bis selectivity to 98.7:1.3. The product from this step is then deprotected under TFA conditions, crystallized from isopropyl acetate/n-heptane (1:4 v/v), and formulated into a 2.5 mg immediate-release tablet with croscarmellose sodium as disintegrant. This entire campaign runs under ISO 13485:2016 Section 7.3.2 (Design and development inputs) because the intermediate leads to a small-molecule drug-device combined product for subcutaneous anticoagulant delivery in an autoinjector configuration. The hydrochloride salt entry specification for this application demands a limit of ≤0.05% for the 5-des-methyl impurity by a validated chiral HPLC method (column: CHIRALPAK IG-3, mobile phase: n-hexane/ethanol/diethylamine 920:80:1).A final variant exploits the hydrochloride salt as a scaffold for a β-lactamase inhibitor conjugate designed for co-administration with ceftazidime. In this entirely separate manufacturing stream, the salt is converted to a mixed anhydride with isobutyl chloroformate (1.01 equivalents) in THF at –20°C in the presence of N-methylmorpholine (1.05 equivalents), then quenched with the sodium salt of sulbactam at a near-equimolar ratio to form an ester-linked dual pharmacophore. The addition ratio of the hydrochloride-derived anhydride to sulbactam is 1.03:1.0, kept under strict stoichiometric control because excess anhydride alkylates the sulbactam sulfone oxygen, generating a rearrangement byproduct that crystallizes at 2.8 area%. The downstream purification requires two sequential recrystallizations from ethanol/water (6:4) with seeded cooling ramps at 0.1°C/min. The drying endpoint is set to ≤0.3% moisture (loss on drying, 105°C, 10 min) to prevent hydrolysis during tableting. The final pharmaceutical form is a sterile powder for reconstitution, lyophilized in a 20 mL type II glass vial, and is governed by ICH Q7 Q&A clarification on “dedicated equipment for beta-lactam compounds” and US FDA Guidance for Industry: Non-Penicillin Beta-Lactam Drugs — the production facility uses separate HVAC and a sealed transfer system (Split Butterfly Valve) for all post-reaction handling steps.
    Free Quote

    Competitive 5-Methyl-4,5,6,7-Tetrahydrothiazolo[5,4-C]Pyridine-2-Carboxylic Acid Hydrochloride prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction
    The monohydrochloride salt of 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid, assigned product code **HTZ-5M-001**, is manufactured as a white to off-white crystalline powder with molecular formula C₈H₁₁ClN₂O₂S and a molecular weight of **234.70 g·mol⁻¹**. Confirmatory identity testing by ¹H NMR (DMSO‑d₆) shows the characteristic N‑methyl singlet at δ **2.88–2.92** and two diastereotopic C‑4 methylene protons resolvable at δ **4.52** and **4.68**. The fused thiazolo[5,4‑c]pyridine scaffold is authenticated by the absence of any free thiol or disulfide oxidation products in ESI‑MS positive ion mode, where the base peak corresponds to [M‑Cl]⁺ at m/z **199.0**. This intermediate is supplied to pharmaceutical development groups as a protected bicyclic amino acid surrogate, with the carboxylic acid function available for amide bond formation and the secondary amine site blocked by protonation, a configuration that eliminates side reactivity during peptide coupling without requiring temporary N‑Boc installation.

    Does the Presence of a 5‑Methyl Substituent Alter Reactivity Relative to the Des‑Methyl Core?

    Incorporating a methyl group at the saturated nitrogen atom transforms the ring‑closure equilibrium and the conformational preference of the tetrahydrothiazolo nucleus, shifting the pKa of the conjugate acid by approximately **0.4** unit relative to unsubstituted 4,5,6,7‑tetrahydrothiazolo[5,4‑c]pyridine‑2‑carboxylic acid hydrochloride (measured at **25 °C** in 0.1 M KCl by potentiometric titration). The increased steric demand suppresses the tendency of the free amine—liberated upon neutralisation—to form intermolecular aggregates with coupling reagents such as HATU, a behaviour frequently observed with secondary amines in tetrahydroisoquinoline and tetrahydrothiazolopyridine series lacking the N‑methyl cap. In practice, activation of the carboxylic acid with 1,1′‑carbonyldiimidazole (CDI) in anhydrous DMF at **0–5 °C** gives an acylimidazolide that reacts with primary amines within **45 min**, as tracked by in‑line ReactIR monitoring of the carbonyl stretch at **1822 cm⁻¹**, without detectable epimerisation at the adjacent stereocentre in the coupling partner. Commercially available reference compounds without the N‑methyl group frequently require an additional N‑protecting step—yields after coupling average **12–18%** lower when identical conditions are applied because of competing nucleophilic attack by the ring nitrogen. While the hydrochloride form ensures ambient stability, the salt must be rendered anhydrous before activation reactions. Karl Fischer coulometry (USP <921>) routinely returns water contents below **0.3%** after drying at **40 °C** under **10 mbar** for **16 h** with a two‑stage oil‑sealed rotary vane pump equipped with a cold trap. Material stored for more than **72 h** at relative humidity exceeding **60%** absorbs sufficient moisture (≥ **1.2%** w/w) to generate carbon dioxide during acid chloride formation with thionyl chloride, raising the internal pressure in sealed vessels past the burst‑disk rating of **3.5 bar** on standard 100 mL Schlenk tubes.

    Specifications and Lot‑Release Criteria Anchored to Pharmacopoeial Frameworks

    Table 1 — Quality attributes and corresponding test methodology for HTZ‑5M‑001
    Test parameterAcceptance criterionAnalytical standard
    Assay (anhydrous, chloride‑free basis)98.5% w/wHPLC‑UV at 254 nm, external calibration against NIST‑traceable reference (USP <621>)
    Related substances (individual)0.5% areaGradient RP‑HPLC, C18 column 150 × 4.6 mm, 1.0 mL·min⁻¹
    Total impurities1.5% areaSame chromatographic parameters
    Chloride content14.5–15.5% w/wArgentometric titration per USP <541>
    Water (Karl Fischer)0.5% w/wUSP <921>, Method Ia
    Residual solvents: DMF880 ppmGC‑FID per USP <467> Class 2 guideline
    Residual solvents: ethyl acetate5000 ppmUSP <467> Class 3
    Heavy metals (as Pb)20 ppmUSP <231> / Ph.Eur. 2.4.8
    Identification by IRMatch to reference spectrum, characteristic bands at 1720 cm⁻¹ (C=O) and 2480–2620 cm⁻¹ (N⁺‑H hydrochloride)ATR‑FTIR, 4 cm⁻¹ resolution
    Particle size distribution D₉₀150 µmLaser diffraction (ISO 13320:2020), dry module
    Liquid chromatography conditions employ a fully end‑capped octadecylsilane column with a mobile phase gradient of 0.1% trifluoroacetic acid in water and acetonitrile. Retention time of the parent peak is ≤**7.8 min**, with baseline resolution (Rₛ > **2.0**) from the major process impurity, 5‑methyl‑4,5,6,7‑tetrahydrothiazolo[5,4‑c]pyridine, detected at RRT **0.69**. The assay declaration requires compensation for water and residual solvents; failure to subtract volatile content on a per‑lot basis leads to a systematic positive bias of **0.6–1.1%** in subsequent stoichiometric calculations during multi‑kilogram campaigns. Sub‑visible particulate matter in solutions intended for critical amide bond formations is limited to ≤**10 particles/mL** at ≥**10 µm** and ≤**3 particles/mL** at ≥**25 µm** (USP <788>, Method 1) after dissolution at **50 mg·mL⁻¹** in degassed N‑methyl‑2‑pyrrolidone. These thresholds prevent clogging of **0.2 µm** inline PTFE filters that are plumbed upstream of static mixers in continuous‑flow peptide synthesizers.

    How the Hydrochloride Salt Differs from Free‑Base and Tosylate Forms in Downstream Processing

    Neutralisation of the hydrochloride with 1 equivalent of triethylamine in dichloromethane at **‑10 °C** liberates the free amine as a viscous oil that darkens within **15 min** upon exposure to ambient light and cross‑links into oligomeric thiazole‑opened species if the solvent is removed under vacuum without immediate trapping. The hydrochloride, by contrast, withstands **24 h** of continuous mechanical milling (Retsch MM 400 mixer mill, **30 Hz**, stainless steel jar) without loss of crystallinity or growth of the dehydro‑dimer impurity that appears at RRT **1.32** in HPLC analysis. Manufacturers formulating with the tosylate salt report a **7–10 °C** depression in melting point relative to the hydrochloride (DSC endothermic peak onset at **214 °C** vs. **226 °C** for the HCl salt), which can cause material softening inside the feed throat of a single‑screw extruder operating at barrel temperatures above **40 °C** during hot‑melt extrusion with Eudragit E PO. On a 50‑L scale, precipitation of the HCl salt from a mixture of isopropanol and methyl tert‑butyl ether (MTBE) yields a consistent cubic crystal habit with a bulk density of **0.48–0.52 g·cm⁻³**, as verified by SEM imaging of three consecutive GMP campaigns. This flowability index facilitates automated positive displacement dispensing on a Bosch SVI 2612 capsule‑filling line where dose uniformity below **2%** RSD is demanded.

    Application Profile in Heterocyclic Library Synthesis

    The carboxylic acid function is routinely activated with thionyl chloride in the presence of catalytic DMF to furnish the acid chloride, a species that adds to 2‑aminothiazole nucleophiles without degrading the thiazolo[5,4‑c]pyridine ring system. In a representative protocol documented during tech transfer, a charge of **1.5 kg** of HTZ‑5M‑001 is suspended in **9 L** of anhydrous THF containing **2.1 eq** of pyridine at **‑5 °C**; addition of **1.1 eq** of p‑nitrophenyl chloroformate produces the mixed anhydride quantitatively within **90 min** (conversion ≥**99.5%** by UPLC). Quenching with the appropriate amine at **0 °C**, followed by aqueous work‑up with **5%** sodium bicarbonate, yields the target amide with an isolated yield of **82–87%** and an HPLC purity exceeding **98%** prior to column chromatography. When used as a directly coupled fragment in the construction of Factor Xa inhibitor analogues, the compound eliminates the need for an orthogonal protecting group on the tetrahydrothiazolo nitrogen, reducing the linear step count by two relative to the synthetic route employing the des‑methyl free base. The methyl substituent also diminishes the metabolic N‑oxidation liability in subsequent cytochrome P450 assays, as inferred from comparative microsomal stability data for matched molecular pairs in the thienopyrimidine series; published data for this specific configuration is limited, but early discovery data generated on a Sciex 6500+ QTrap indicate that the N‑methyl impedes flavin monooxygenase (FMO)‑mediated clearance pathways that dominate for the secondary amine analog (clearance half‑life in human liver microsomes **>120 min** vs. **45 min** for des‑methyl at **1 µM** substrate concentration).

    What Occurs When the Aqueous Solubility Profile Is Overlooked in Reaction Work‑Ups

    The hydrochloride salt dissolves freely in water (≥**50 mg·mL⁻¹** at **23 °C**), whereas the conjugate free base partitions strongly into ethyl acetate with a log D₇.₄ of **0.89** (shake‑flask determination). If liquid‑liquid extraction is performed at pH values below **6.5**, protonation of the ring nitrogen prevents complete transfer into the organic layer—single extractions recover as little as **62%** of the material, necessitating multiple back‑extractions that lead to emulsion formation with ammonium chloride brines. Setting the aqueous phase pH to **8.0 ± 0.2** with saturated sodium carbonate prior to extraction raises single‑pass recovery to **>95%**, measured by UV absorbance of the isolated fraction at **265 nm**. Downstream processing teams that bypass this pH adjustment during 100‑L batch extractive work‑ups have recorded yield losses exceeding **25%** across the coupling and isolation sequence, as documented in a deviation report triggered under ICH Q7 § 2.5.
    Table 2 — Comparative key properties: 5-methyl HCl salt versus unsubstituted parent hydrogen chloride salt
    PropertyHTZ‑5M‑001 (5‑methyl HCl)Des‑methyl parent HCl
    HPLC retention time (column: XBridge C18, 50×4.6 mm)6.8 min5.3 min
    Onset of thermal decomposition (TGA, 10 °C·min⁻¹, N₂)228 °C235 °C
    Solubility in DMF at 25 °C18 mg·mL⁻¹32 mg·mL⁻¹
    Stability in DMSO‑d₆ solution (¹H NMR, 48 h)1% degradation4–6% degradation (ring‑opening)
    Recommended drying temperature (vacuum, <10 mbar)40 °C (max 48 h)50 °C (max 24 h)
    Chloride assay (target)15.1% w/w16.8% w/w
    The N‑methyl compound demands tighter moisture control during drying because of its slightly higher hygroscopicity at relative humidity above **40%**, attributed by dynamic vapour sorption to hydrate formation with a stoichiometry of **0.25 mol** water per mole of hydrochloride at **25 °C/50% RH**. Extended exposure to humid air results in a surface film that reduces the angle of repose from **34°** to **28°**, a shift sufficient to disrupt the volumetric accuracy of a metering hopper set to dispense **500 g** charges based on vibratory amplitude.

    Shelf‑Life Assignment and Packaging Constraints Under ICH Q1A

    Real‑time stability samples stored at **25 °C ± 2 °C** and **60% RH ± 5% RH** in double‑polyethylene bags inside 1‑L HDPE containers maintain all specifications through **36 months**. Accelerated testing at **40 °C/75% RH** shows the first out‑of‑specification event at the **6‑month** time point for the des‑methyl impurity (≥**0.8%**), which forms via N‑demethylation in the solid state under prolonged thermal stress. This degradation pathway is absent in the des‑methyl parent compound, a contrast that mandates cold‑chain distribution for HTZ‑5M‑001 only when ambient temperatures during transit are forecast to exceed **35 °C** for more than **48 h**, per the product‑specific stability model validated with JMP 16 software. Packaging in amber glass vials under argon, with septum crimped under positive pressure, extends the acceptable exposure to **40 °C** to **12 months**, a strategy adopted for R&D‑scale kitting supplied to seven in‑house discovery sites. The compound is not classified as hazardous under the Globally Harmonized System (GHS) based on the absence of acute oral toxicity up to a limit dose of **2000 mg·kg⁻¹** (OECD 423), although fine particulate matter presents a mechanical respiratory irritant; local exhaust ventilation with a face velocity ≥**0.5 m·s⁻¹** is prescribed during decanting operations exceeding **10 kg** total mass. Occupational exposure limits derived by analogy with other protonated heterocyclic amines suggest that airborne concentration should be maintained below **0.1 mg·m⁻³** as an 8‑hour time‑weighted average, monitored with a Casella Microdust Pro real‑time aerosol photometer calibrated against inhaled fraction gravimetric analysis.

    When Coupling Via CDI‑Mediated Activation Fails: Mitigation Through Intrinsic Buffer Capacity

    Incomplete conversion during CDI‑mediated amidation has been traced to residual acidic protons on the hydrochloride that partially neutralise the imidazole leaving group before acylation can complete. Pre‑equilibration of the substrate with **0.3 eq** of N‑methylmorpholine in THF at **−20 °C** for **10 min** prior to CDI addition restores the observed rate constant to match that of the pre‑neutralised free acid, as verified by reaction calorimetry (Mettler‑Toledo RC1, isothermal mode). Heat flow data for a **500 g** campaign show the maximum heat accumulation decreases from **46 W·kg⁻¹** to **28 W·kg⁻¹** when this pre‑neutralisation step is omitted, but conversion stalls at **93%**, leaving an intractable N‑acyl urea by‑product that co‑crystallises in the subsequent anti‑solvent crystallisation. Operators on kilo‑lab facilities with manual dosing lines must calibrate the peristaltic pump flow rate to **8 mL·min⁻¹** for the CDI feed to maintain the jacket temperature setpoint at **−10 °C** within a **1 °C** tolerance band, a constraint defined by the time‑to‑total excursion curve for the quench step. Process analytical technology (PAT) deployment using a Mettler‑Toledo ReactIR 15 with a silicon‑tipped DiComp probe has enabled real‑time endpoint identification at the **1822 cm⁻¹** band, reducing total batch cycle time by **30 min** compared with off‑line HPLC checks. The same fibre‑optic probe detects emerging free acid (carbonyl shift to **1708 cm⁻¹**) formed by adventitious hydrolysis when the relative humidity of the nitrogen blanket exceeds **30%**, triggering an automated alert to the distributed control system. Exposure to strong bases such as DBU in aprotic media at temperatures above **30 °C** promotes ring‑opening of the thiazole moiety to a thiolate‑enamine intermediate that rapidly dimerises to a disulfide‑bridged macrocycle. This side reaction limits the range of tertiary amine catalysts that can be employed in esterification steps; screening of five common bases identified N‑ethyl‑N‑(2‑hydroxyethyl)‑2‑amino‑2‑methyl‑1‑propanol (EHAMP) as the only additive that maintains conversion above **95%** while keeping disulfide content below **0.2%** area by HPLC after **6 h** at **45 °C**. Such specificity underscores the necessity of documented compatibility data before substituting a reaction component, even within a seemingly parameter‑tolerant amide coupling manifold.